Hansa Medical’s prospectus for the new share issue of MSEK 29 has been published

23 May 2011, 14:30

Regulatory information

On 12 May 2011, Hansa Medical’s annual meeting of shareholders resolved to execute a new share issue of MSEK 29 with preferential rights for Hansa Medical’s shareholders. The Company has prepared a prospectus (in Swedish only) regarding this new share issue which has been approved and registered by the Swedish Financial Supervisory Authority on 23 May. The new share issue prospectus and a more general information brochure (attached and in Swedish only) will also be distributed to Hansa Medical’s shareholders. The prospectus and application forms can be obtained, free of charge, from Avanza Bank on telephone +46 8-5622 5122 or www.avanza.se. Shareholders whose shares are held by a nominee should contact their nominee for information and instructions.

Summary of the share issue
With the aim of financing Hansa Medical’s continued product development and in order to achieve crucial development milestones, Hansa Medical’s annual meeting of shareholders resolved, on 12 May 2011, to execute a new share issue of 5,794,776 shares. Those individuals registered as shareholders on record day, 19 May 2011, are entitled to subscribe to the new shares, whereby one existing share entitles three subscription rights. Four subscription rights entitle to subscription of one new share. Hansa Medical’s largest shareowner, Bo Håkansson, through company, has committed, on the basis of a subscription commitment, to subscribe to his portion of the new share issue, equivalent to approximately 42 percent. Hansa Medical has also entered into an agreement with Bo Håkansson through company, for an issuing guarantee, equivalent to than portion of the new share issue not covered by the subscription commitment, approximately 58 percent.

Background and motivation
Hansa Medical develops innovative biopharmaceuticals and diagnostic methods in partnership with large, market-established companies, and also independently. Today there are three primary development projects underway: IdeS, anti-alpha-11 and HMD-301. The motive for the proposed new share issue is to achieve the critical and highly valuable development milestones. Hansa Medical intends to initiate clinical studies of the drug candidate, IdeS, to accomplish a registration and launch of diagnostic method HMD-301, to identify an anti-alpha.11 drug candidate appropriate for clinical development and to, possibly, bring a new and innovative research finding to the development stage.

Schedule for the new share issue
16 May 2011, Last trading day for the share with right to participate in the share issue
19 May 2011, Record day
23 May 2011, Publication of the prospectus
26 May – 14 June 2011, Subscription period
26 May – 9 June2011, Subscription rights trading
17 June 2011, Outcome published

Avanza Bank is the financial advisor and Fredersen Advokatbyrå is the legal advisor of Hansa Medical.

Files

wkr0001.pdf

For further information, please contact:
Emanuel Björne, CEO Hansa Medical AB
Mobile: +46 707 17 54 77
E-mail: emanuel.bjorne@hansamedical.com

Hansa Medical is a biopharmaceutical development company focused on inflammation. The company develops innovative biopharmaceuticals and diagnostics in partnership with major companies with market presence as well as under full Hansa Medical management. At present, three primary product candidates are in development; IdeS, anti-alpha-11 and HMD-301. Novel research projects and product candidates are generated through academic collaborations and in-house development. Hansa Medical is publicly traded at NASDAQ OMX First North under ticker symbol HMED. Remium AB is Certified Adviser to Hansa Medical.